Oprah, Amy Schumer and Sharon Osbourne have all spoken publicly about using GLP-1 weight loss medicines. Their stories made headlines — but headlines can mislead. Here is what the clinical evidence actually says, and what UK patients can realistically expect.
Over the past three years, celebrity weight loss jabs have become one of the most searched topics in the UK. Names like Ozempic, Wegovy and Mounjaro — all GLP-1 medicines, meaning drugs that mimic a natural gut hormone to reduce appetite — have moved from specialist clinics into everyday conversation. Much of that shift has been driven by high-profile celebrity disclosures.
Over the past two years, more celebrities have spoken publicly about Ozempic, Wegovy and Mounjaro, helping bring weight loss medicines into mainstream conversation.
But what do those celebrity stories actually tell us? And how much of it applies to an ordinary woman in the UK considering her options? The answer requires separating the headlines from the evidence.
Which Celebrities Have Spoken Publicly About GLP-1 Medicines?
Several well-known figures have confirmed using GLP-1 medicines, either directly or through representatives.
Oprah Winfrey confirmed in a 2024 interview with People magazine that she had used a weight loss medication as part of her treatment plan. She described the drug as a tool, not a solution, and emphasised that lifestyle changes remained central to her results.
Amy Schumer discussed her experience with Ozempic (semaglutide) in media interviews, saying the side effects — nausea and muscle loss — led her to stop the treatment. She was candid that the experience was not straightforwardly positive.
Sharon Osbourne spoke to various media outlets about losing a significant amount of weight using a GLP-1 medicine, but later expressed concern about losing too much weight and struggling to stop the drug without regaining.
Tracy Morgan and Meghan Trainor have also publicly confirmed using GLP-1 treatments, with Trainor speaking positively about her experience in interviews in 2024.
These accounts are real and they are relevant. But they share a common problem: they are individual stories, not clinical data. According to the NHS, individual responses to any medicine vary considerably based on starting weight, diet, activity levels and medical history.
What Do Celebrity Experiences Actually Reflect?
Celebrity accounts tend to capture the most dramatic outcomes, because those are the stories that get published. A celebrity who lost modest weight and experienced tolerable side effects rarely makes the news.
According to the STEP clinical trial programme, published in the New England Journal of Medicine, patients using semaglutide (the active ingredient in Ozempic and Wegovy) lost an average of around 15 percent of their body weight over 68 weeks. That is a meaningful result — but it is an average. Some patients lost significantly more. Others lost considerably less.
According to a 2022 study published in the journal Diabetes, Obesity and Metabolism, side effects including nausea, vomiting and diarrhoea affected a substantial proportion of trial participants, particularly in the early weeks of treatment. Amy Schumer’s experience with nausea is clinically consistent — it is common, not unusual.
Sharon Osbourne’s concern about difficulty stopping treatment also reflects real evidence. According to a 2022 paper in the journal Obesity, patients who stopped semaglutide after the trial regained approximately two-thirds of their lost weight within a year. This is not a side effect of the drug — it reflects the underlying biology of obesity, which does not simply disappear when medication stops.
Mounjaro (tirzepatide) has shown even stronger results in trials. According to the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, patients on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight. This puts it ahead of any other currently licensed weight loss medicine in the UK. If you want to understand how Mounjaro compares to other options, our Weight Loss Jabs Guide covers all the current treatments in plain English.
The challenge with celebrity weight loss jabs coverage is that it rarely mentions these numbers, or their limitations. It focuses on transformation images and personal testimony. For a UK patient making a real financial and health decision, that is not enough information.
What This Means For UK Patients
If you are considering a GLP-1 treatment after seeing celebrity coverage, that curiosity is completely understandable. But there are three things worth remembering.
First, celebrities often have personal trainers, nutritionists, private medical teams and controlled schedules. Their results are not necessarily reproducible in a normal working life.
Second, celebrity weight loss jabs coverage almost never discusses cost, eligibility or what happens when you stop. In the UK, Wegovy is available on the NHS through specialist services, but access remains limited. Mounjaro is currently available privately. Prices for private prescriptions typically range from £150 to £250 per month, according to current UK private clinic pricing data.
Third, the evidence shows these medicines work — but they work best as part of a medically supervised programme that includes dietary and behavioural support. Any UK clinic offering these drugs without that support structure deserves scrutiny. Our UK Clinic Reviews section helps you identify which providers meet that standard.
If you are just starting to explore your options, the best place to begin is our Start Here guide, which explains the full landscape of treatments available to UK patients right now.
Frequently Asked Questions
Did Oprah Winfrey use Ozempic or Wegovy?
Oprah Winfrey confirmed using a weight loss medication in a 2024 interview with People magazine, but did not specify which GLP-1 drug by name. She described it as one tool within a broader health programme that included diet and exercise.
Are the side effects celebrities describe medically accurate?
Yes. Nausea, fatigue and gastrointestinal discomfort are among the most commonly reported side effects in clinical trials. According to the STEP trials, nausea affected approximately 44 percent of participants on semaglutide at some point during treatment, particularly in the early weeks.
Can I get the same results as a celebrity using Ozempic or Mounjaro?
Clinical trials show meaningful average weight loss — around 15 percent for semaglutide and up to 22.5 percent for tirzepatide, according to published trial data in the New England Journal of Medicine. However, individual results vary widely, and celebrities typically have access to additional professional support that most patients do not.
What happens when you stop taking a GLP-1 medicine?
According to a 2022 paper published in the journal Obesity, most patients who stopped semaglutide regained approximately two-thirds of their lost weight within 12 months. This does not mean the medicine failed — it reflects the chronic nature of obesity as a medical condition, which often requires long-term management.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
